Wong, J. S. L., Kwok, G. G. W., Tang, V., Li, B. C. W., Leung, R., Chiu, J., . . . Yau, T. (2021). Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors. J Immunother Cancer.
Citación estilo ChicagoWong, Jeffrey Sum Lung, et al. "Ipilimumab and Nivolumab/pembrolizumab in Advanced Hepatocellular Carcinoma Refractory to Prior Immune Checkpoint Inhibitors." J Immunother Cancer 2021.
Cita MLAWong, Jeffrey Sum Lung, et al. "Ipilimumab and Nivolumab/pembrolizumab in Advanced Hepatocellular Carcinoma Refractory to Prior Immune Checkpoint Inhibitors." J Immunother Cancer 2021.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.